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Abstract
Purpose To gain more insight into the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-
related quality of life (HRQoL) in a population-based sample of colorectal cancer (CRC) patients up to 2 years after diagnosis.
Methods All newly diagnosed CRC patients from four hospitals in the Netherlands were eligible for participation in an ongoing
prospective cohort study. Patients (n = 340) completed questions on CIPN (EORTCQLQ-CIPN20) and HRQoL (EORTCQLQ-
C30) before initial treatment (baseline) and 1 and 2 years after diagnosis.
Results Among chemotherapy-treated patients (n = 105), a high sensory peripheral neuropathy (SPN) level was reported by 57%
of patients at 1 year, and 47% at 2-year follow-up, whereas a highmotor peripheral neuropathy (MPN) level was reported by 47%
and 28%, at years 1 and 2, respectively. Linear mixed model analyses showed that SPN and MPN symptoms significantly
increased from baseline to 1-year follow-up and did not return to baseline level after 2 years. Patients with a high SPN or MPN
level reported a worse global quality of life and a worse physical, role, emotional, cognitive, and social functioning compared
with those with a low SPN or MPN level.
Conclusions Future studies should focus on understanding the mechanisms underlying CIPN so targeted interventions can be
developed to reduce the impact of CIPN on patient’s lives.
Implications for cancer survivors Patients need to be informed of both CIPN and the impact on HRQoL.
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Abbreviations
PROFILES Patient Reported Outcomes
Following Initial treatment
and Long term Evaluation
of Survivorship
PROs Patient-reported outcomes
NCR Netherlands Cancer Registry




SPN Sensory peripheral neuropathy
MPN Motor peripheral neuropathy
MPN Autonomic peripheral neuropathy
CRC Colorectal cancer
Colorectal cancer (CRC) is the third most common cancer
among men and women [1]. In 2019, 12,900 patients were
diagnosed in the Netherlands. Fortunately, survival rates have
improved remarkably as a result of earlier detection and
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improved treatment strategies. In the past 20 years, the 5-year
survival rate has increased from 54 to 66% in the Netherlands
[2]. The increasing number of CRC survivors highlights the
need to focus on the side effects of cancer and its treatment.
A common and severe side effect is chemotherapy-induced
peripheral neuropathy (CIPN), which is the result of damage
to the peripheral nerves caused by chemotherapy. The preva-
lence differs depending on type of chemotherapeutic agent
and method of assessment. However, a meta-analysis reported
an overall prevalence of 68% in the first month after chemo-
therapy, and 30% at 6 months or more [3]. There is currently
no strategy available to prevent CIPN and pharmacological
options to manage established CIPN are limited [4].
Therefore, the development of severe CIPN is often a reason
for dose reduction or even discontinuation of the chemother-
apeutic agent, compromising the efficacy of treatment and
patient survival [5].
CIPN symptoms in CRC are primarily sensory (e.g., tin-
gling, numbness, and pain in the extremities), but can be mo-
toric (e.g., cramps and loss of strength), or autonomic (e.g.,
dizziness after standing up and blurry vision) as well [5].
These symptoms can cause problems with regular daily activ-
ities, which are likely to compromise health-related quality of
life (HRQoL). This was indeed the conclusion of a review on
CIPN and HRQoL [6]. Among patients with CRC, several
studies examined the relationship between CIPN and
HRQoL [6–10]. We previously showed in an analyses of
1643 CRC survivors 2–11 years after diagnosis that neuropa-
thy was negatively related with all scales of the EORTCQLQ-
C30 questionnaire [7]. However, most studies, including ours
have been cross-sectional. In addition, while several studies
among CRC patients have examined the course of CIPN over
time, most studies did either not include a CIPN measurement
before the start of chemotherapy, did not examine the course
longer than 1 year after diagnosis, or did not distinguish be-
tween sensory (SPN), motor (MPN), and autonomic (APN)
peripheral neuropathy (PN) [11–13].
Gaining more insight into the course of CIPN and its influ-
ence on HRQoL is important to be able to inform and guide
CRC patients and clinicians in their decision-making regard-
ing treatment. Therefore, our aim is to prospectively examine
(1) the prevalence and course of SPN, MPN, and APN and (2)
their association with HRQoL among a population-based




The PROCORE study is an ongoing prospective, population-
based study among CRC patients, aimed to examine the
impact of CRC and its treatment on patient-reported out-
comes. Data collection was performed within PROFILES
(Patient Reported Outcomes Following Initial Treatment and
Long Term Evaluation of Survivorship), a registry for the
physical and psychosocial impact on cancer and its treatment
[14]. PROFILES is directly linked to the Netherlands Cancer
Registry (NCR) that collects data from all newly diagnosed
cancer patients [2]. Patients were recruited from four Dutch
hospitals: Elisabeth-TweeSteden hospital, Catharina hospital,
Elkerliek hospital, and Máxima Medical Centre.
All patients newly diagnosed with CRC as a primary tumor
between January 2016 and January 2019 were invited to par-
ticipate. Exclusion criteria were the following: previous can-
cer diagnosis (except for basal cell carcinoma), cognitive lim-
itations, and the inability to read or write Dutch. All eligible
patients were included shortly after diagnosis, before the start
of initial treatment. However, some patients who were previ-
ously diagnosed with cancer and those who already started
treatment were also included. Therefore, patients were exclud-
ed for analysis if (1) they were previously diagnosed with
cancer and reported baseline EORTC QLQ-CIPN20 scores
> 0, or (2) they already started chemotherapy.
Data collection
From their research nurse or case manager, patients received
an information package, containing an information letter, in-
formed consent form, and the first questionnaire. In the first
questionnaire, patients could indicate if they wanted to receive
the follow-up questionnaires online. After patients had provid-
ed their consent, follow-up questionnaires were sent 4 weeks
after surgery (when applicable), and 1 and 2 years after diag-
nosis. As the questionnaire 4 weeks after surgery did not con-
tain questions on CIPN, it was not included in the analysis.
The PROCORE study was approved by the Medical research
E t h i c s Commi t t e e s Un i t e d ( a pp r ov a l n umbe r
NL51119.060.14).
Sociodemographic and clinical characteristics
Patients’ sociodemographic (i.e., age, sex) and clinical infor-
mation (e.g., cancer type, clinical stage, surgery (yes/no), che-
motherapy (yes/no), and radiotherapy (yes/no)) was obtained
from patients’ medical records by the NCR [2]. Educational
level and partner status were assessed in the questionnaire.
Comorbidity was assessed with the adapted Self-
administered Comorbidity Questionnaire [15].
PN
PN symptoms were assessed with the EORTC QLQ-CIPN20
[16], which contains three subscales, assessing SPN, MPN,
and APN symptoms. Items are measured on a Likert scale,
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ranging from (1) not at all to (4) very much. Scores are trans-
formed to a 0–100 scale, with higher scores representing more
complaints [17].
Because PN symptoms can also be present in people with-
out cancer, which are then associated with comorbidity and
normal aging [18], we wanted to distinguish patients with a
high PN level from those with symptoms in the normal range.
Therefore, Dutch age and sex-specific normative EORTC
QLQ-CIPN20 data [18] and the minimal clinically important
difference (MCID) of the CIPN20 (i.e., 2.5 for SPN and 2.6
for MPN) were used [19]. For example, in the general popu-
lation, men aged 60–69 years reported a mean SPN score of
2.9. Therefore, in the current study, men in this age group
were categorized into “high SPN” if they had a sensory score
of ≥ 5.4 (2.9 + 2.5), and into “low SPN” if they reported scores
< 5.4. No categorization was done for APN, as no MCID is
available [19].
Health-related quality of life
The EORTC QLQ-C30 was used to assess HRQoL [20]. In
this study, only the global health status/QoL scale and the five
functioning scales were used. Items are scored on a Likert
scale from (1) not at all to (4) very much, except for the global
QoL scale, which ranges from (1) very poor to (7) excellent.
Scores were linearly transformed to a 0–100 scale, with higher
scores representing better QoL/functioning [17].
Statistical analyses
NCR data on sociodemographic and clinical characteristics
enabled us to compare eligible patients and respondents, and
those who completed baseline and either 1-year follow-up or
2-year follow-up with patients who completed all question-
naires, using t tests for continuous variables and chi-square (or
Fisher’s exact) tests for categorical variables. All other analy-
ses are based on patients who completed at least two question-
naires. First, differences in patient characteristics between pa-
tients who received chemotherapy and those who did not were
assessed with t tests for continuous variables and chi-square
tests for categorical variables.
Then, logistic regression analyses were performed to detect
differences in PN symptoms at 1-year and 2-year follow-up be-
tween patients who were given chemotherapy and those who
were not. For these analyses, the individual items of the
EORTC QLQ-CIPN20 were used and the answer categories
“quite a bit” and “very much” were combined. Analyses were
adjusted for age, diabetes mellitus, osteoarthritis, and rheumatoid
arthritis, which are variables known or expected to impact PN.
The SPN, MPN, and APN courses were examined using
linear mixed models (LMM), with maximum likelihood esti-
mation and an unstructured covariance matric with a 2-level
structure (i.e., repeated time points [lower level], patients
[higher level]). Time was analyzed as a regular categorical
predictor with three levels (i.e., three time points). These anal-
yses were adjusted for age, diabetes mellitus, osteoarthritis,
and rheumatoid arthritis. Differences in SPN, MPN, and
APN between patients with or without chemotherapy were
examined similarly, but without time as a predictor.
Unstandardized regression coefficients (E) are reported.
Clinically important differences were determined using the
MCID [19].
To detect differences in HRQoL between patients accord-
ing to the stability of their SPN or MPN levels, t tests were
conducted. For this, patients were categorized into “ever SPN”
if they reported high SPN on at least one of the three time
points; otherwise, they were categorized into “never SPN.”
The same was done for MPN. Clinically important differences
were determined using EORTC QLQ-C30 guidelines [21].
Finally, the impact of SPN and MPN on HRQoL over time
was examined with LMM. SPN and MPN were included as
dichotomous variables (high vs. low level of SPN/MPN) and
analyzed as time-varying predictors, while for the confound-
ing background variables age, sex, partner status, education
level, tumor type, stage, osteoarthritis, rheumatoid arthritis,
and diabetes mellitus baseline characteristics were used.
Analyses were performed using SPSS 22 (IBM SPSS
Statistics for Windows, version 22.0 Armonk, NY: IBM Corps
USA). p values < 0.05 were considered statistically significant.
Results
Patient characteristics
Of the 713 CRC patients whowere invited to the study, 66.9%
(n = 477) completed the questionnaire at baseline, 50.4% (n =
359) at 1-year follow-up, and 28.5% (n = 203) at 2-year fol-
low-up (Fig. 1.). As the study is still ongoing, not all patients
have yet received the questionnaire at 1-year and 2-year fol-
low-up. Compared with all patients eligible for participation,
respondents were younger (70 vs. 67 years, p < 0.001), more
often male (56% vs. 61%, p = 0.04), they received chemother-
apy more often (26% vs. 31%, p = 0.02), and surgery less
often (100% vs. 98%, p < 0.001). Furthermore, they were less
often diagnosed with rectosigmoid cancer (5% vs. 3%, p =
0.02), they more often had stage III cancer (29% vs. 37%, p =
0.003), and an unknown stage (1% vs. 2%, p < 0.001), and
less often stage IV cancer (11% vs. 4%, p < 0.001). No differ-
ences in sociodemographic and clinical characteristics were
found between patients who completed at least two question-
naires and patients who completed all three questionnaires
(data not shown).
Further analyses were done among respondents who com-
pleted at least two questionnaires (n = 340). Among these pa-
tients, chemotherapy-treated patients (n = 105, 31%) were
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younger, they less often had at least 2 comorbidities, and they
more often had a higher disease stage compared with those not
treated with chemotherapy (n = 235, 69%) (Table 1). They
were also more often treated with radiotherapy, but less often
713 CRC patients were asked to participate in the study
Eligible patients (N=1599)*
Age (M=69.6, SD=10.6) Tumor location Surgery (N=1599, 100%)
Female sex (N=708, 44%) Colon (N=1075, 67%) Chemotherapy (N=418, 26%)             
Rectum (N=442, 28%) Radiotherapy (N=257, 16%)             
Rectosigmoid (N=82, 5%)
236 CRC patients actively refused or did not return the 
baseline questionnaire
444 CRC patients were invited for 1-year follow-up
• 15 CRC patients did not receive the questionnaire yet, as this study is still 
ongoing
2-year follow-up
477 (67%) CRC patients completed the baseline 
questionnaire
1-year follow-up
18 CRC patients died
58 (22%) CRC patients actively refused or did not return the 
questionnaire  
359 (81%)† CRC patients completed the questionnaire at 1-year follow-up
9 CRC patients died
261 CRC patients were invited for 2-year follow-up
• 183 CRC patients did not receive the questionnaire yet, as this study is still 
ongoing
85 (19%) CRC patients actively refused or did not return the 
questionnaire (yet): 
• 83 CRC patients actively refused or did not return the questionnaire 
• 2 CRC patients did receive the questionnaire but handed it in after 
data analysis
203 (78%)† CRC patients completed the questionnaire at 2-year follow-up
Stage at diagnosis
I   (N=531, 33%)




340 CRC patients were included in the analysis of the current study:
•  26 CRC patients were previously diagnosed with a carcinoma and reported peripheral neuropathy symptoms at 
baseline
• 16 CRC patients had chemotherapy before completing the baseline questionnaire (2 CRC patients who had surgery 
before baseline and 1 CRC patient who received radiotherapy before baseline were not excluded)
• 4 CRC patients did not complete the EORTC QLQ-CIPN20 at baseline
• 2 CRC patients were excluded for a combination of the above reasons
• Only CRC patients who completed at least the baseline questionnaire and either 1-year follow-up or 2-year follow-
up were included (N=89 patients were excluded)
Fig. 1 Flowchart of the study. *Characteristics of eligible CRC patients were obtained from the Netherlands Cancer Registry. †Among chemotherapy-
treated CRC patients only, 76% completed 1-year follow-up and 79% completed 2-year follow-up
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received surgery. No data on chemotherapy regimen (e.g.,
type of chemotherapy administered, number of chemotherapy
cycles, and dosage) was available.
Peripheral neuropathy
At 1-year follow-up, chemotherapy-treated patients reported
tingling fingers or hands, tingling toes or feet, numbness in
fingers or hands, numbness in toes or feet, and trouble han-
dling small objects significantly more often compared with
those not treated with chemotherapy (Table 2). At 2-year fol-
low-up, they still more often reported tingling toes or feet and
numbness in toes or feet.
The prevalence of a high SPN and MPN level (using
MCID + normscores) was also examined. While for SPN,
no differences between chemotherapy-treated patients and
those without chemotherapy were found at baseline (11%
vs. 16%; p = 0.17); chemotherapy-treated patients did more
often report a high SPN level at 1-year (57% vs. 24%;
p < 0.001) and 2-year follow-up (47% vs. 31%; p = 0.03).
Table 1 Sociodemographic and
clinical characteristics at baseline
of colorectal cancer patients,
stratified by chemotherapy
Chemotherapy
(n = 105 (31%))
No chemotherapy
(n = 235 (69%))
p value
Age (mean, SD) 63.8 (8.8) 67.5 (8.4) < 0.001
Female sex 33 (31%) 99 (42%) 0.06
Partner (yes) 93 (89%) 197 (84%) 0.29
Education levela 0.43
Low 6 (6%) 23 (10%)
Medium 67 (64%) 146 (63%)
High 32 (31%) 64 (28%)
Tumor location 0.99
Colon 76 (72%) 168 (72%)
Rectum/rectumsigmoid 29 (28%) 66 (28%)
Colon and rectumsigmoid 0 (0%) 1 (0.4%)
TNM stage < 0.001
I 1 (1%) 103 (44%)
II 8 (8%) 86 (37%)
III 92 (88%) 35 (15%)
IV 4 (4%) 6 (3%)
Unknown 0 (0%) 5 (2%)
Tumor differentiation grade 0.21
Well differentiated 1 (1%) 1 (0.4%)
Moderately differentiated 90 (86%) 181 (77%)
Poorly differentiated 4 (4%) 16 (7%)
Unknown 10 (10%) 37 (16%)
Radiotherapy (yes) 27 (26%) 26 (11%) < 0.001
Surgery (yes) 98 (93%) 235 (100%) < 0.001
Number of comorbidities 0.048
None 33 (32%) 62 (27%)
One 41 (39%) 71 (31%)
Two or more 30 (29%) 100 (43%)
Comorbidities associated with PNb
Osteoarthritis 20 (19%) 53 (23%) 0.47
Rheumatoid arthritis 7 (7%) 13 (6%) 0.68
Diabetes mellitus 5 (5%) 26 (11%) 0.06
Variables may deviate from 100% due to rounding off
SD standard deviation
Italicized p values indicate statistically significance
a Education: low (no or primary school); medium (lower general secondary education or vocational training); high
(pre-university education, high vocational training, university)
bMost frequent comorbidities associated with peripheral neuropathy
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Regarding MPN, chemotherapy-treated patients reported a
high MPN level more often compared with those not treated
with chemotherapy, but only at 1-year follow-up (47% vs.
32%; p = 0.02). No differences were found at baseline (15%
vs. 23%; p = 0.13) and 2-year follow-up (28% vs. 35%; p =
0.34).
Course of peripheral neuropathy
For chemotherapy-treated patients, SPN increased significant-
ly at 1-year follow-up. Furthermore, while the SPN mean
score then did significantly decrease at 2-year follow-up, it
remained significantly higher compared with baseline. All
changes in mean score were significant (all three p < 0.001)
and clinically relevant (Fig. 2). For patients not treated with
chemotherapy, SPN increased at 1-year (p = 0.001, not clini-
cally relevant) and at 2-year follow-up remained stable, but
still significantly higher compared with baseline (p < 0.001,
clinically relevant). Finally, chemotherapy-treated patients
reported a higher SPN mean score at 1-year (p < 0.001) and
2-year follow-up (p = 0.001). These differences were clinical-
ly relevant.
For MPN, the mean score increased for both
chemotherapy-treated patients and those not treated with
chemotherapy at 1-year (both p < 0.001), and at 2-year
follow-up remained stable and still significantly higher
compared with baseline (p = 0.004 and p < 0.001).
However, the significant differences were only clinically
relevant for chemotherapy-treated patients. Moreover,
chemotherapy-treated patients reported a higher MPN
mean score, but only at 1-year follow-up (p = 0.007, clin-
ically relevant).
F ina l ly , APN showed a stab le course among
chemotherapy-treated patients, while for those not treated with
chemotherapy, there was a small increase at 1-year follow-up
(p = 0.048, not clinically relevant). No differences were found
between chemotherapy-treated patients and those not treated
with chemotherapy.
Table 2 Peripheral neuropathy symptoms among colorectal cancer patients at 1-year and 2-year follow-up, stratified by chemotherapy










Sensory symptoms and problems
1. Tingling fingers or hands 25 (25%) 13 (6%) < 0.001 7 (12%) 7 (5%) 0.28
2. Tingling toes or feet 36 (36%) 10 (4%) < 0.001 10 (17%) 5 (4%) 0.008
3. Numbness in fingers or hands 15 (15%) 2 (1%) < 0.001 3 (5%) 2 (2%) 0.28
4. Numbness in toes or feet 20 (20%) 5 (2%) < 0.001 7 (12%) 4 (3%) 0.02
5. Shooting or burning pain in fingers or hands 6 (6%) 4 (2%) 0.16 2 (3%) 2 (2%) 0.31
6. Shooting or burning pain in toes or feet 8 (8%) 7 (3%) 0.07 5 (9%) 6 (5%) 0.20
9. Trouble standing or walking 10 (10%) 4 (2%) 0.002 4 (7%) 4 (3%) 0.99
10. Trouble distinguishing temperature of hot and cold water 2 (2%) 2 (1%) 0.53 2 (3%) 0 (0%) 0.99
18. Trouble hearing 9 (9%) 20 (9%) 0.50 6 (10%) 11 (8%) 0.42
Motor symptoms and problems
7. Cramps in hands 4 (4%) 7 (3%) 0.79 2 (3%) 7 (5%) 0.67
8. Cramps in feet 4 (4%) 7 (3%) 0.76 4 (7%) 6 (5%) 0.47
11. Trouble holding a pen which made writing difficult 1 (1%) 4 (2%) 0.50 1 (2%) 2 (2%) 0.93
12. Trouble handling small objects (e.g., buttoning a blouse) 15 (15%) 9 (4%) < 0.001 5 (9%) 6 (5%) 0.10
13. Trouble opening jar/bottle due to loss of strength in hands 12 (12%) 17 (8%) 0.28 3 (5%) 11 (9%) 0.59
14. Trouble walking because your feet come down to hard 3 (3%) 1 (0.4%) 0.08 2 (3%) 1 (1%) 0.27
15. Trouble walking stairs or standing up from a chair
due to weakness in legs
8 (8%) 11 (5%) 0.28 3 (5%) 4 (3%) 0.54
19. Only for those driving cars: Trouble driving due to use of pedals 2 (2%) 2 (1%) 0.60 2 (4%) 0 (0%) 0.99
Autonomic symptoms and problems
16. Dizziness after standing up 5 (5%) 9 (4%) 0.60 1 (2%) 5 (4%) 0.53
17. Blurry vision 2 (2%) 8 (4%) 0.83 1 (2%) 4 (3%) 0.69
20. Only for men: Trouble getting or maintaining an erection 20 (30%) 40 (35%) 0.79 12 (32%) 33 (47%) 0.21
Italicized p values indicate statistically significance. The number of patients reported in this table reflects the patients who answered “quite a bit” or “very
much” on the EORTC QLQ-CIPN20 items
Analyses were adjusted for age, diabetes mellitus, osteoarthritis, and rheumatoid arthritis








































Before treatment Year 1 Year 2
Autonomic peripheral neuropathy
Chemotherapy No chemotherapy
Fig. 2 Course of sensory, motor,
and autonomic peripheral
neuropathy among colorectal
cancer patients, stratified by
chemotherapy. A higher score on
the scales indicates more
neuropathy symptoms. The scale
in this figure ranges from 0 to 50
for clear visibility of the course of
the peripheral neuropathy
symptoms, while total scores of
the EORTC QLQ-CIPN20 range
from 0 to 100
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Peripheral neuropathy and HRQoL
In further analyses, both patients who received chemo-
therapy and those who did not were included in the anal-
yses. At baseline, patients in the “ever high SPN” group
reported worse global quality of life, and worse physical,
emotional, cognitive, and social functioning compared
with patients who never reported high SPN (Fig. 3).
However, only the difference in global quality of life
and cognitive functioning were of (small) clinical rele-
vance. At 1-year and 2-year follow-up, patients in the
“ever high SPN” group reported worse scores on all six
HRQoL scales, which were of small to medium clinical
relevance.
For MPN, patients in the “ever high MPN” reported worse
scores on all six HRQoL scales at all three time points (Fig. 3).
However, at baseline, only the differences in global quality of
life and physical, cognitive, and social functioning were of
(small) clinical relevance. At 1- and 2-year follow-up, all dif-
ferences were clinically relevant (small to medium).
Between-patients and within-patients effects of pe-
ripheral neuropathy on HRQoL
CRC patients with a high SPN level reported a worse global
quality of life (E = − 11.87, p < 0.001) and a worse physical
(E = − 11.34, p < 0.001), role (E = − 11.46, p < 0.001), emo-
tional (E = − 9.59, p < 0.001), cognitive (E = − 13.43,
p < 0.001), and social functioning (E = − 10.62, p < 0.001)
compared with those with a low SPN level (between-patients
effects). Furthermore, patients who changed from a low to a
high SPN level over time showed a decrease in physical (E =
− 8.24, p < 0.001), role (E = − 8.83, p < 0.001), cognitive (E =
− 6.47, p < 0.001), and social (E = − 5.72, p = 0.001) function-
ing, while patients who changed from a high to a low SPN
level over time showed improvements in these areas (within-
patients effects).
For MPN, those with a high MPN level also reported a
worse global quality of life (E = − 11.86, p < 0.001) and a
worse physical (E = − 14.16, p < 0.001), role (E = − 13.35,
p < 0.001), emotional (E = − 8.36, p < 0.001), cognitive (E =
− 12.81, p < 0.001), and social (E = − 11.10, p < 0.001)
functioning compared with those with a low MPN level. In
addition, patients who changed from a low to a high MPN
level over time showed a decrease in global quality of life
(E = − 6.62, p < 0.001) and physical (E = − 10.59, p < 0.001),
role (E = − 14.91, p < 0.001), cognitive (E = − 5.41,
p < 0.001), and social (E = − 7.59, p < 0.001) functioning,
while those who changed from a high to a low MPN level
over time showed improvements on these scales.
Discussion
In this longitudinal study among CRC patients, we first showed
that, at 1-year follow-up, chemotherapy-treated patients more
often reported tingling fingers or hands, tingling toes or feet,
numbness in fingers or hands, numbness in toes or feet, and
trouble handling small objects, compared with those not treated
with chemotherapy. At 2-year follow-up, they still more often
reported tingling and numbness in toes or feet. These results are
in line with prior research, in which it was also found that
symptoms in the hands are more prominent during and shortly
after chemotherapy, while symptoms in the feet are more prom-
inent months after chemotherapy [7, 22, 23]. Also, the overall
CIPN prevalence is reported to be 30% at 6 months or more
after chemotherapy [3]. While in this study the prevalence rate
of MPN at 2-year follow-up (28%) supports those findings, the
reported SPN (47%) is much higher.
Looking at the course of PN, both SPN and MPN were
impacted by chemotherapy, and the reported SPN and MPN
did not return to baseline level after 2 years. However, at 2-
year follow-up, the MPN level did decline to the same level as
those not treated with chemotherapy. The finding that SPN
was mostly impacted by chemotherapy is supported by previ-
ous studies [7, 11, 13]. The question remains whether SPN
symptoms will continue to decrease after 2 years, or that it
remains a chronic problem after this period of time. The small
increase in PN symptoms in those not treated with chemother-
apy could be due to older age and an increase in age- and PN-
related comorbidity, such as diabetes mellitus, rheumatoid
arthritis, and osteoarthritis. Also, we only had data on chemo-
therapy as primary treatment while it is possible that patients
in the “no chemotherapy” group did receive chemotherapy as
secondary treatment.
Regarding the association between PN and HRQoL, CRC
patients with a high SPN or MPN level reported a worse
global quality of life and a worse functioning compared with
those with a low level. Previous cross-sectional studies among
CRC patients have found similar results. For example, our
previous study among CRC survivors 2–11 years after diag-
nosis showed that those with many neuropathy symptoms
reported significant and clinically relevant worse HRQoL
scores on all EORTC QLQ-C30 subscales [7]. Another study
among oxaliplatin-treated CRC survivors up to 7 years post
 Fig. 3 Course of health-related quality of life for colorectal cancer
patients according to them ever or never reporting high sensory periph-
eral neuropathy (a) or motor peripheral neuropathy (b). *Significant dif-
ference between patients who “ever” reported high SPN/MPN and those
who “never” reported high SPN/MPN, but of no clinical relevance.
‡Significant difference, of small clinical relevance. †Significant differ-
ence, of medium clinical relevance. ¥Significant difference, of large clin-
ical relevance. The scale in this figure ranges from 50 to 100 for clear
visibility of the association between peripheral neuropathy and health-
related quality of life, while total scores of the EORTC QLQ-C30 range
from 0 to 100
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chemotherapy also found that PN was associated with worse
HRQoL [8].
The results of this study regarding both the long-lasting
course of SPN and the impact of PN on HRQoL indicate that
it is crucial to inform patients and clinicians about CIPN and
its impact on patients’ lives. In addition, currently no preven-
tive treatment for CIPN is available. More studies aiming to
improve our understanding of the mechanisms underlying the
development of CIPN are needed, so targeted interventions
can be developed. Several alternative chemotherapy options
are available to prevent (severe) CIPN. Evidence shows that
shortened durations (3 vs. 6 months) of FOLFOX or CAPOX
chemotherapy can be given to stage III colon cancer patients,
without compromising survival [24]. CAPOX is preferred, as
it results in a lower incidence of long-lasting SPN compared
with FOLFOX chemotherapy [25]. For established (painful)
CIPN, duloxetine is the only agent recommended in the treat-
ment of CIPN [4]. In addition, preliminary empirical evidence
suggests that non-pharmacological treatments such as exercise
[26] and cognitive-behavioral therapy [27] may be effective in
preventing and/or treating (painful) CIPN. More studies are
needed to provide more evidence for the effectiveness of these
non-pharmacological treatments. Also, future research should
examine possible sociodemographic, clinical, and psycholog-
ical factors that predict the onset and persistence of CIPN.
The present study has some limitations. First, data on type
of chemotherapy, number of chemotherapy cycles, and dose
reduction were not available, while these factors are important
determinants of CIPN and thereby could have impacted our
results [3]. The lack of a clinician-based assessment of CIPN
is another limitation, as patient-reported assessments of CIPN
should preferably be combined with clinician-rated neurolog-
ical assessment tools [28]. However, especially patient-
reported assessment seems important, as healthcare profes-
sionals often underestimate the severity and frequency of neu-
ropathy symptoms [29]. Furthermore, generalization of the
results of this study should be done with caution, as eligible
patients and the respondents of this study did show some
differences in sociodemographic and clinical characteristics.
Moreover, as the PROCORE study is still ongoing, not all
patients received the questionnaires at 1-year and 2-year fol-
low-up. While no differences in sociodemographic and clini-
cal characteristics were found between patients who complet-
ed both baseline and either 1-year or 2-year follow-up and
those who completed all three questionnaires, this could have
impacted (the strength of) our findings. Finally, it remains
unknown whether those lost to follow-up stopped participat-
ing due to PN in their hands. If so, this may have resulted in an
underestimation of our findings.
Despite these limitations, this is, to the best of our knowl-
edge, the first longitudinal study that examined the association
between CIPN and HRQoL among CRC patients up to 2 years
after diagnosis. In addition, by examining not only between-
patients effects but also within-patient effects in the associa-
tion between CIPN and HRQoL, a stronger support for cau-
sality is provided.
In conclusion, the results of this study indicate that espe-
cially SPN symptoms are still prevalent 2 years after diagno-
sis. In addition, both SPN and MPN were significantly asso-
ciated with a worse HRQoL. Therefore, it is crucial that pa-
tients are informed of both CIPN and the impact on HRQoL.
Due to the currently limited treatment options, clinicians may
also offer support to CRC survivors by monitoring for the
symptoms and supporting survivors in their search for a solu-
tion, for example, by informing them about possible benefits
of exercise and cognitive-behavioral therapy. Future studies
should focus on increasing the understanding of the mecha-
nisms underlying both the development of CIPN and CIPN
chronicity, so targeted interventions can be developed to re-
duce the impact of CIPN on patients’ lives.
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